WO2011009059A3 - Méthode de traitement ou de prévention du cancer - Google Patents

Méthode de traitement ou de prévention du cancer Download PDF

Info

Publication number
WO2011009059A3
WO2011009059A3 PCT/US2010/042306 US2010042306W WO2011009059A3 WO 2011009059 A3 WO2011009059 A3 WO 2011009059A3 US 2010042306 W US2010042306 W US 2010042306W WO 2011009059 A3 WO2011009059 A3 WO 2011009059A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treating
preventing
inhibiting
animal
Prior art date
Application number
PCT/US2010/042306
Other languages
English (en)
Other versions
WO2011009059A2 (fr
Inventor
Phillip A. Dennis
M. Christine Hollander
Marc Nicklaus
Megan Peach
Sherry R. Chemler
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
The Research Foundation Of State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Research Foundation Of State University Of New York filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2011009059A2 publication Critical patent/WO2011009059A2/fr
Publication of WO2011009059A3 publication Critical patent/WO2011009059A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une méthode d'inhibition de Akt, d'activation de AMPK, d'inhibition de mTOR, de traitement ou de prévention du développement du cancer, et/ou de prévention de la progression de lésions prémalignes en cancer chez un animal, comprenant l'administration à l'animal d'une quantité efficace d'un composé tel que décrit ici, par exemple, le NSC 743411, dont la formule est présentée ci-dessous. La méthode implique l'utilisation de ces composés en tant qu'agents uniques ou en combinaison avec une chimiothérapie, une thérapie biologique, ou une radiothérapie classique. L'invention concerne en outre de nouveaux composés et de nouvelles compositions pharmaceutiques destinés à être utilisés dans le traitement ou la prévention du développement du cancer ou la prévention de la progression de lésions prémalignes en cancer. La présente invention concerne également une méthode d'inhibition de CSF1R.
PCT/US2010/042306 2009-07-17 2010-07-16 Méthode de traitement ou de prévention du cancer WO2011009059A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22632809P 2009-07-17 2009-07-17
US61/226,328 2009-07-17

Publications (2)

Publication Number Publication Date
WO2011009059A2 WO2011009059A2 (fr) 2011-01-20
WO2011009059A3 true WO2011009059A3 (fr) 2011-04-21

Family

ID=42668073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042306 WO2011009059A2 (fr) 2009-07-17 2010-07-16 Méthode de traitement ou de prévention du cancer

Country Status (1)

Country Link
WO (1) WO2011009059A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404571A (zh) * 2022-03-18 2024-02-01 共信醫藥科技股份有限公司 藥物組成物及化療劑用於製備治療癌症之藥物的用途
CN115073495B (zh) * 2022-08-09 2024-03-19 苏州大学 一种吲哚啉类化合物及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5116874A (en) * 1985-09-23 1992-05-26 Eli Lilly And Company Anti-tumor method and compounds
EP0550157A1 (fr) * 1991-12-20 1993-07-07 Eli Lilly And Company Compositions antitumorale et méthode de traitement
EP0602878A1 (fr) * 1992-12-10 1994-06-22 Eli Lilly And Company Diarylsulfonylurées et leur utilisation comme agents antitumoraux
WO2005040101A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates connectes a l'acyluree et a la sulfonyluree
EP1859797A1 (fr) * 2005-02-28 2007-11-28 Eisai R&D Management Co., Ltd. Nouvelle utilisation concomitante d'un compose de sulfonamide avec un agent anti-cancer
WO2010005534A2 (fr) * 2008-06-30 2010-01-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs des protéasomes pour l’induction sélective de l’apoptose dans les cellules cancéreuses
WO2010129596A1 (fr) * 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Inhibiteurs de la pkm2 destinés à être utilisés dans le traitement du cancer
WO2010130665A1 (fr) * 2009-05-12 2010-11-18 F. Hoffmann-La Roche Ag Spirodérivés azacycliques en tant qu'inhibiteurs de la hsl

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5116874A (en) * 1985-09-23 1992-05-26 Eli Lilly And Company Anti-tumor method and compounds
EP0550157A1 (fr) * 1991-12-20 1993-07-07 Eli Lilly And Company Compositions antitumorale et méthode de traitement
EP0602878A1 (fr) * 1992-12-10 1994-06-22 Eli Lilly And Company Diarylsulfonylurées et leur utilisation comme agents antitumoraux
WO2005040101A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates connectes a l'acyluree et a la sulfonyluree
EP1859797A1 (fr) * 2005-02-28 2007-11-28 Eisai R&D Management Co., Ltd. Nouvelle utilisation concomitante d'un compose de sulfonamide avec un agent anti-cancer
WO2010005534A2 (fr) * 2008-06-30 2010-01-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs des protéasomes pour l’induction sélective de l’apoptose dans les cellules cancéreuses
WO2010129596A1 (fr) * 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Inhibiteurs de la pkm2 destinés à être utilisés dans le traitement du cancer
WO2010130665A1 (fr) * 2009-05-12 2010-11-18 F. Hoffmann-La Roche Ag Spirodérivés azacycliques en tant qu'inhibiteurs de la hsl

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AVDEENKO A P ET AL: "Thiocyanation of N-Arylsulfonyl-, N-Aroyl-, and N-(N-Arylsulfonyl)benzimidoyl)-1,4-benzoquinone Iminies", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, CONSULTANTS BUREAU, US, vol. 45, no. 3, 29 April 2009 (2009-04-29), pages 408 - 416, XP002586945, ISSN: 1070-4280 *
BAXTER I ET AL: "Preparation and some reactions of 6-arylsulphonimidobenzoxazol-2(3H)-one", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1970 (1970-01-01), pages 850 - 853, XP008122990, ISSN: 0022-4952, DOI: DOI:10.1039/J39700000850 *
COLLINS I ET AL: "Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 4, 15 February 2006 (2006-02-15), pages 1255 - 1273, XP025133010, ISSN: 0968-0896, [retrieved on 20060215], DOI: DOI:10.1016/J.BMC.2005.09.055 *
D. A. GUERTIN, D. M. SABATINI: "Defining the role of mTOR in cancer", CANCER CELL, vol. 12, July 2007 (2007-07-01), pages 9 - 22, XP002599504 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 April 2005 (2005-04-15), "Benzoic acid, 4-(1-piperidinylsulfonyl)-, 2-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-2-oxoethyl ester", XP002599503, retrieved from STN accession no. RN 848580-83-6 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 30 December 2004 (2004-12-30), "Benzoic acid, 3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl], 2-[(3-cyano-2-thienyl)amino]-2-oxoethyl ester", XP002599502, retrieved from STN accession no. RN 805306-56-3 *
DATABASE ZREGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 28 July 2005 (2005-07-28), ""Acetic acid, 2-[[4-[[(4-ethoxyphenyl)sulfonyl]imino]-1,4-dihydro-1-oxo-2-naphthalenyl]thio]-"", XP002615085, retrieved from STN accession no. RN 857494-31-6 *
FAIVRE S ET AL: "Current development of mTOR inhibitors as anticancer agents", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/NRD2062, vol. 5, no. 8, 1 August 2006 (2006-08-01), pages 671 - 688, XP002587702, ISSN: 1474-1784 *
FUJITA, S. AND SANO K.: "reduction of quinones and quinonemonosulfonimides with N,N-diethylhydroxylamine", JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 5, 1979, pages 2647 - 2649, XP007916530 *
HAYAKAWA ET AL: "Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 17, 19 July 2007 (2007-07-19), pages 5837 - 5844, XP022152373, ISSN: 0968-0896, DOI: DOI:10.1016/J.BMC.2007.05.070 *
LIU Q ET AL: "MTOR mediated anti-cancer drug discovery", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES 2009 ELSEVIER LTD GBR LNKD- DOI:10.1016/J.DDSTR.2009.12.001, vol. 6, no. 2, December 2009 (2009-12-01), pages 47 - 55, XP027103036, ISSN: 1740-6773 *
MORGENSZTERN D ET AL: "PI3K/Akt/mTOR pathway as a target for cancer therapy", ANTI-CANCER DRUGS, LIPPINCOTT WILLIAMS & WILKINS, US; NL LNKD- DOI:10.1097/01.CAD.0000173476.67239.3B, vol. 16, no. 8, 1 January 2005 (2005-01-01), pages 797 - 803, XP008092039, ISSN: 0959-4973 *
PIAO WENHUA ET AL: "Induction of G2/M phase arrest and apoptosis by a new synthetic anti-cancer agent, DW2282, in promyelocytic leukemia (HL-60) cells", BIOCHEMICAL PHARMACOLOGY, vol. 62, no. 11, 1 December 2001 (2001-12-01), pages 1439 - 1447, XP007916529, ISSN: 0006-2952 *
SHERMAN E S ET AL: "Pyrrolidine and piperidine formation via copper(II) carboxylate-promoted intramolecular carboamination of unactivated olefins: Diastereoselectivity and mechanism", JOURNAL OF ORGANIC CHEMISTRY 20070511 AMERICAN CHEMICAL SOCIETY US, vol. 72, no. 10, 11 May 2007 (2007-05-11), pages 3896 - 3905, XP002615086, DOI: DOI:10.1021/JO070321U *
SUN E ET AL: "Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984)", BIOCHEMICAL PHARMACOLOGY 1995 US LNKD- DOI:10.1016/0006-2952(95)02050-0, vol. 50, no. 9, 1995, pages 1461 - 1468, XP007916528, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2011009059A2 (fr) 2011-01-20

Similar Documents

Publication Publication Date Title
JO2848B1 (en) Organic compounds
MY155961A (en) Chemical compounds 251
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
NZ619259A (en) Inhibitors of influenza viruses replication
TW200833663A (en) Therapeutic agents
WO2012083122A8 (fr) Inhibiteurs de la réplication du virus de la grippe
TNSN07419A1 (en) Methods for treating drug resistant cancer
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
NZ598489A (en) Combination therapy for treating proliferative diseases
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2009003719A3 (fr) Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
WO2010075287A3 (fr) Composés et procédés pour le traitement de la douleur et d'autres maladies
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737173

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10737173

Country of ref document: EP

Kind code of ref document: A2